SGLT2 inhibitor treatment was associated with a significant decrease in epicardial adipose tissue volume or thickness compared to control (SMD -1.79; 95% CI -2.91 to -0.66; p<0.01).
Meta-Analysis
Do SGLT2 inhibitors as a class reduce epicardial adipose tissue volume/thickness compared to a control group?
SGLT2 inhibitors significantly reduce epicardial adipose tissue volume and thickness, which may represent a potential mechanism for their beneficial effects on heart failure outcomes.
Effect estimate: SMD -1.79 (95% CI -2.91 to -0.66)
p-value: p=<0.01
Abstract Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a groundbreaking class of antidiabetic medications, renowned for their glucose-lowering effects and cardiovascular benefits. Recent studies have suggested that SGLT2 inhibitors may extend their influence beyond glycemic control to impact adipose tissue physiology, particularly within the epicardial adipose depot. Epicardial adipose tissue (EAT), an actively secretory organ surrounding the heart, has been implicated in the modulation of cardiovascular risk. Purpose This meta-analysis aims to systematically review and synthesize existing literature on the effects of SGLT2 inhibitors on epicardial adipose tissue. Methods We performed a literature search for studies assessing epicardial adipose tissue before and after treatment with a SGLT2 inhibitor compared to a control group. We excluded reviews, editorials, case reports/case series, and studies that did not use SGLT2 inhibitors or did not have a control group for comparison. The main outcome of interest was the change in EAT volume/thickness at follow-up. Effect sizes are presented as standardized mean difference (SMD) with their corresponding 95% confidence intervals (CIs) and were pooled based on a random-effects model. The leave-one-out sensitivity analysis was used for further validation of the findings. Publication bias was assessed by funnel plot inspection and egger’s regression test. Results The literature search yielded 49 results. After application of the exclusion criteria, a total of 6 studies were selected for data extraction and inclusion in the meta-analysis. Accordingly, we detected that treatment with an SGLT2 inhibitor was associated with decreased EAT volume/thickness (SMD -1.79, 95% CI -2.91 to -0.66, p0.01). There was substantial between-study heterogeneity (I2: 94%, p0.01). Results remained robust even after exclusion of any single study. Funnel plot inspection and egger’s regression test did not indicate the presence of publication bias. Conclusion This meta-analysis suggests that SGLT2 inhibitors use is associated with a reduction in EAT volume/thickness, posing as a potential mechanism of their beneficial effects in heart failure outcomes.Figure
Theofilis et al. (Tue,) reported a meta-analysis. Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Control group was evaluated on Change in epicardial adipose tissue (EAT) volume/thickness at follow-up (SMD -1.79, 95% CI -2.91 to -0.66, p=<0.01). SGLT2 inhibitor treatment was associated with a significant decrease in epicardial adipose tissue volume or thickness compared to control (SMD -1.79; 95% CI -2.91 to -0.66; p<0.01).